Stockreport
NEW DATA SUPPORT THE USE OF BICTEGRAVIR TABLET REGIMEN TO TREAT PEOPLE WITH HIV AND INDIVIDUALS WITH HIV/HBV-COINFECTION IN ASIA [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Regimen for the Treatment of People with HIV Initiating Therapy and Individuals with Prior Antiretroviral Therapy – – Subanalysis of a Phase 3 Randomized Controlled Trial Demonstrates B/F/TAF Single-Tablet Regimen Well Tolerated and Effective Treatment in Adults of Asian Descent Living with HIV, as well as Those with HIV/HBV Co-Infected who are ART-Naïve – HONG KONG June 27, 2024 /PRNewswire/ -- Gilead Sciences, Inc. today unveiled findings from two comprehensive studies examining the effectiveness and tolerability of the B/F/TAF single-tablet regimen for the treatment of adults with HIV who are treatment-naïve and treatment-experienced, as well as ART-naïve, HIV/HBV co-infected adults of Asian descent. The data selected for presentation at the hybrid Asia-Pacific AIDS and Co-Infections Conference (APACC) 2024, taking place 27 June to 29 June in Hong Kong , marks the first time that these findings have been featured at a regional conference. BICtegravir Single Tablet Regimen Asi
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year [Yahoo! Finance][Yahoo! Finance]
- Global Autologous Stem Cell & Non-Stem Cell Therapies Market: $5.5B in 2024 to $22.2B by 2029, CAGR 32.3% | MarketsandMarkets™ [Yahoo! Finance][Yahoo! Finance]
- GILEAD'S TWICE-YEARLY LENACAPAVIR DEMONSTRATED 100% EFFICACY AND SUPERIORITY TO DAILY TRUVADA® FOR HIV PREVENTION [Yahoo! Finance][Yahoo! Finance]
- Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors [Yahoo! Finance][Yahoo! Finance]
- Corporate Reputation of Pharma in 2023/2024: The Patient Perspective and Views of 2,500+ Patient Groups - Pharma Corporate Reputation Falls from COVID Highs [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- GILD's page on the SEC website
- More